ENDRA Life Sciences (NASDAQ:NDRA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports.

According to Zacks, “ENDRA Life Sciences Inc. is a developer of enhanced ultrasound technologies. ENDRA Life Sciences Inc. is based in Ann Arbor, United States. “

Separately, HC Wainwright reiterated a “buy” rating and set a $6.00 price target on shares of ENDRA Life Sciences in a research note on Monday, November 18th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. ENDRA Life Sciences currently has an average rating of “Buy” and a consensus target price of $4.00.

NASDAQ:NDRA traded down $0.01 during trading hours on Tuesday, reaching $1.98. 1,900 shares of the company’s stock were exchanged, compared to its average volume of 193,008. The firm has a market capitalization of $15.83 million, a price-to-earnings ratio of -1.39 and a beta of 1.52. The company has a 50-day moving average of $1.45 and a 200 day moving average of $1.35. The company has a quick ratio of 1.54, a current ratio of 1.61 and a debt-to-equity ratio of 0.26. ENDRA Life Sciences has a 1-year low of $0.62 and a 1-year high of $3.49.

ENDRA Life Sciences (NASDAQ:NDRA) last issued its quarterly earnings results on Wednesday, November 13th. The company reported ($0.46) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.27). Research analysts forecast that ENDRA Life Sciences will post -0.98 EPS for the current fiscal year.

A hedge fund recently bought a new stake in ENDRA Life Sciences stock. Virtu Financial LLC acquired a new position in shares of ENDRA Life Sciences Inc (NASDAQ:NDRA) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 28,541 shares of the company’s stock, valued at approximately $30,000. Virtu Financial LLC owned about 0.38% of ENDRA Life Sciences as of its most recent filing with the SEC. 12.24% of the stock is currently owned by hedge funds and other institutional investors.

About ENDRA Life Sciences

ENDRA Life Sciences Inc develops medical imaging technology based on the thermos-acoustic effect that improves the sensitivity and specificity of clinical ultrasound. It offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding.

See Also: Analyst Ratings Trading

Get a free copy of the Zacks research report on ENDRA Life Sciences (NDRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.